News

ARS Pharmaceuticals Announces the Appointment of Two New Board Members

Expansion of Board of Directors Adds Commercialization and Financial Expertise,  Further Augments Clinical and Scientific Acumen of Medical and Scientific Advisory Board  SAN DIEGO – June 18, 2019 – ARS Pharmaceuticals, Inc., a pharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions...

ARS Pharmaceuticals Announces Results from EPI-04 Clinical Study of ARS-1 Intranasal Epinephrine Spray in Allergy Patients with Allergic Rhinitis

Results demonstrate rapid epinephrine absorption with an overall pharmacokinetic profile comparable to epinephrine injection in allergy-induced patients SAN DIEGO--(BUSINESS WIRE)--ARS Pharmaceuticals, Inc., a pharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions potentially leading to anaphylaxis, today announced results from its EPI-04...

ARS Pharmaceuticals Announces FDA Fast Track Designation for ARS-1 Intranasal Epinephrine Spray

San Diego, Calif. – February 19, 2019 – ARS Pharmaceuticals, Inc., a pharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions potentially leading to anaphylaxis, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for ARS-1,...